PeploBio

Executive Summary

PeploBio is a UK-based precision medicine diagnostics company founded in 2020, specializing in molecular and serology techniques with a focus on AI/ML integration. The company operates a UKAS-accredited ISO15189 pathology laboratory in Guildford, offering rapid turnaround diagnostic services. By leveraging advanced molecular diagnostics and artificial intelligence, PeploBio aims to elevate precision medicine, enabling more accurate and timely disease detection and monitoring. Currently in Phase 2 development stage, the company is privately held and has not disclosed total funding or valuation. With a strong foundation in molecular and immunology expertise, PeploBio is well-positioned to capture growth in the rapidly evolving diagnostics market, particularly in personalized medicine and infectious disease testing. However, given limited public information on revenue and partnerships, the company faces typical early-stage risks including commercial scalability and regulatory hurdles.

Upcoming Catalysts (preview)

• TBDLaunch of Next-Generation Sequencing (NGS) based diagnostic panel50% success
• TBDStrategic partnership with major NHS trust for rapid COVID-19 variant detection40% success
• Q3 2026Completion of Series A funding round to scale laboratory operations70% success